A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Novartis
University of Pittsburgh
Jazz Pharmaceuticals
University of Florida
Cornerstone Pharmaceuticals
Mayo Clinic
Enzon Pharmaceuticals, Inc.
M.D. Anderson Cancer Center